GANX - Gain Therapeutics, Inc.
1.95
0.060 3.077%
Share volume: 163,540
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$1.89
0.06
0.03%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-12-2023 | 08-10-2023 | 11-14-2023 | 03-26-2024 | 05-14-2024 | 08-08-2024 | 11-14-2024 | 03-27-2025 | |
| Total revenue | 55.180 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 55.180 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| -100.00% | nan% | nan% | nan% | nan% | nan% | nan% | |||
| Operating expenses | 5.285 M | 7.731 M | 4.885 M | 4.407 M | 4.378 M | 8.183 M | 4.459 M | 3.331 M | |
| Selling general and admin | 2.494 M | 3.743 M | 2.518 M | 2.033 M | 1.871 M | 3.745 M | 1.837 M | 2.106 M | |
| Research and development | 2.791 M | 3.988 M | 2.367 M | 2.374 M | 2.507 M | 4.438 M | 2.622 M | 1.225 M | |
| Total expenses | 5.285 M | 7.731 M | 4.885 M | 4.407 M | 4.378 M | 8.183 M | 4.459 M | 3.331 M | |
| 46.29% | -36.81% | -9.78% | -0.67% | 86.92% | -45.51% | -25.29% | |||
| Operating income | -5.230 M | -7.731 M | -4.885 M | -4.407 M | -4.378 M | -8.183 M | -4.459 M | -3.331 M | |
| Ebit | -5.230 M | -7.731 M | -4.885 M | -4.407 M | -4.110 M | -8.226 M | -4.580 M | -3.315 M | |
| Pretax income | -5.121 M | -7.661 M | -4.697 M | -4.709 M | -3.994 M | -8.142 M | -4.475 M | -3.263 M | |
| 49.62% | -38.70% | 0.27% | -15.19% | 103.84% | -45.04% | -27.07% | |||
| Income tax | 16.728 K | 26.589 K | 21.456 K | 14.502 K | 19.874 K | 1.209 K | 10.994 K | 504.738 K | |
| Net income basic | -5.137 M | -7.688 M | -4.718 M | -4.724 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| -49.65% | 38.63% | -0.12% | 100.00% | ||||||
| Net income | -5.137 M | -7.688 M | -4.718 M | -4.724 M | -4.014 M | -8.143 M | -4.486 M | -3.768 M | |
| -49.65% | 38.63% | -0.12% | 15.02% | -102.86% | 44.91% | 15.99% |
